

DIMENSIONAL ANALYSIS

Dimension 1 - Acute Intoxication and/or Withdrawal Potential

The ASAM Criteria has no Dimension 1 information to report.

Dimension 2 - Biomedical Conditions and Complications

In Dimension 2, the patient's needs regarding biomedical issues can be met at multiple levels, including: Level 4, Level 4-BioMed.

Dimension 3 - Emotional, Behavioral or Cognitive Conditions and Complications

In Dimension 3, the patient's needs regarding emotional, behavioral or cognitive conditions and complications can be met at multiple levels, including: Level 2.1-COC, Level 2.1-COE, Level 2.5-COC, Level 3.3-COC, Level 3.3-COE, Level 3.7-COC, Level 4-COE.

Dimension 4 - Readiness to Change

In Dimension 4, the patient's needs regarding readiness to change can be met at multiple levels, including: Level 0.5, Level 1, Level 2.1, Level 2.1-COE, Level 3.5, Level 3.5-COE.

Dimension 5 - Relapse, Continued Use or Continued Problem Potential

In Dimension 5, the patient's needs regarding relapse, continued use or continued problem potential can be met at multiple levels, including: Level 3.1, Level 3.1-COE.

Dimension 6 - Recovery Environment

In Dimension 6, the patient's needs regarding recovery environment can be met at multiple levels, including: Level 0.5, Level 1, Level 1-COE, Level 2.1, Level 3.3, Level 3.3-COE, Level 3.5, Level 3.5-COE, Level 3.7, Level 3.7-COE.

Levels of Care

+

Meets Criteria

COC

Co-occurring Capable

WM

Withdrawal Management

COE

Co-occurring Enhanced

BIO

Biomedical Conditions

Dimension	0.5	1	OTS	2.1	2.5	3.1	3.2	3.3	3.5	3.7	4
Dimension 1	+	+									
Dimension 2											+
Dimension 3				COC COE	COC			COC COE		COC	COE
Dimension 4	+	+		+					+		
Dimension 5						+		COE			
Dimension 6	+	+		+				+	+	+	

Please refer to Appendix for more details regarding [Dimensional Analysis definitions](#).

ACCESS TO TREATMENT ISSUES

The following items related to access to treatment were noted while completing this assessment:

1. Daisy has indicated that she is unsteady on her feet, problems with walking or balance, such that she could easily fall or have trouble getting around or using stairs.
2. The patient has problems with ambulation or mobility that would make it difficult to attend treatment.
3. The patient does not have a valid driver's license.
4. Ms Duck has 1 other people who depend on her for the majority of their food, shelter, and other support needs.
5. The patient is unable to locate or safely get to community resources.
6. Daisy does not have continuous monitoring available on an outpatient basis for the next 8 to 24 hours.
7. The clinician deduced from the interview or has information that indicates that she may have a major neurocognitive disorder, a category which includes alcohol amnesic-confabulatory type, or Alzheimer's Disease.
8. The clinician deduced from the interview or has information that indicates that the patient's current behavior may be inconsistent with reliable self-care, safety, or an ability to participate effectively in treatment.
9. Daisy cannot access services such as assertive community treatment and intensive case management.

FINAL LEVEL OF CARE RECOMMENDATIONS

The patient should be considered for multiple levels of care. The treatment team should consider her history carefully and place the patient in the level of care that best suits her presentation.

1. The patient is best initially treated in a Level 3.7 -- medically monitored intensive inpatient treatment program.
2. Ms Duck has a co-occurring Mental Disorder that meets the stability criteria for placement in a Co-Occurring Capable program.
3. Daisy may require initial treatment in a Level 4 program.
4. In addition to the assessment and treatment plan activities in Level 4, she requires equal attention to the her co-occurring mental disorder.

The patient met criteria for placement in Level 4, but she indicated that this would be unacceptable to her for treatment.

**Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
™ Copyright ©2013 American Psychiatric Association. All Rights Reserved.*

Unless authorized in writing by the APA, no part may be reproduced or used in a manner inconsistent with the APA's copyright. This prohibition applies to unauthorized uses or reproductions in any form.

The American Psychiatric Association is not affiliated with and is not endorsing this product.

Trademark:

**DSM and DSM-5 are registered trademarks of the American Psychiatric Association, and are used with permission herein. Use of these terms is prohibited without permission of the American Psychiatric Association.*

Use of this trademark does not constitute endorsement of this product by the American Psychiatric Association.